Search results for " VLP" in Articles / App Notes
Article
Accelerating VLP purification process development
Indeed, a method for the large-scale production of VLPs is production in suspension cell culture, and extracting the VLPs from the cell culture supernatant is a time and labor-intensive process.
…
Article
Virus-like Particles as Therapeutic Moieties of the Future
The uniformity and self-assembly of VLPs, along with their ability to withstand chemical modifications primarily on the outer surface, make them flexible and stable alternatives to nanoparticles, such…
Article
Genetic Vaccine Platforms Demonstrate Their Potential
In addition, some protein-, VLP-, and killed virus-based non-live vaccines require addition of an adjuvant to improve their immunogenicity due to their non-replicating nature.
Spo…
Article
Addressing the Challenges in Downstream Processing Today and Tomorrow
Similar to viral vectors, VLPs present unique challenges because of their large size (2.5 x106 kDa). Q (14 kDa) is the most commonly used VLP. It is derived from the structural coat protein of this vi…
Article
Ensuring Viral Safety of Viral Vaccines and Vectors
Sf9 cells are a common substrate for biological products such as VLPs.
These contamination events highlight the limitations of current technologies; more vigilance is needed. Consequences of va…
Article
Generating a Fully Processed Antibody
Many VLPs, for example, require two or more proteins to be produced in the right proportion to get the correct viral structure to mimic the virus itself.
In the case of a protein needing cleavage …
Article
Novel Vaccine Technologies Meet the Need for Pandemic and Therapeutic Solutions
Novavax’ seasonal and pandemic influenza vaccines consist of VLPs or recombinant particles with matrix proteins that provide a structure onto which the surface proteins hemagglutinin and neuraminidase…